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ABSTRACT
Neuropathic pain (NP) is type of chronic pain that is common and often difficult 
to treat. Clinicians may be guided by a number of published guidelines and 
algorithms for the management of neuropathic pain. It is important for every 
clinician to know the quality of guidelines. The availability of current guideline 
in Asian countries is not well understood. Critical appraisal of NP guidelines in 
Asia has not performed, yet. The aim of this study was to appraise the quality 
of pharmacological treatment from neuropathic pain guidelines in Asia. 
Systematic searches were conducted by using combination of keywords i.e NP, 
Asia, and guideline. Guidelines evaluation was using appraisal of guidelines 
for research & evaluation II (AGREE II) instrument. The result interpreted as 
(i) a strongly recommended for use in practice if most domains scored above 
50%; (ii) recommended for use with some modification if most domains scored 
between 30% to 50%; or (iii) not recommended for use in practice if most 
domains scored below 30%. After matched to inclusion and exclusion criteria 
there were 5 guidelines left: a guideline from Philippines, China, South Korea, 
Malaysia and Middle East. All of guidelines are recommended for use with 
some modification. The guidelines mention that first line treatment for NP are 
tricyclic antidepressants, selective norepinephrine reuptake inhibitor (SNRI) 
and alpha 2-delta ligand calcium channel blocker (CCB). Most of the evidences 
come from peripheral NP. There were limited evidences for the treatment of 
central neuropathic pain (central post stroke pain and pain after spinal cord 
injury). All the existing guideline mention, that the first line treatment for 
neuropathic are the tricyclic antidepressants, SNRI and alpha 2-delta ligand 
CCB.
ABSTRAK
Nyeri neuropatik (NP) adalah tipe nyeri kronis yang umum dan seringkali 
sulit diobati. Dokter dipandu oleh sejumlah pedoman dan algoritma 
yang diterbitkan untuk manajemen NP. Penting bagi setiap dokter untuk 
mengetahui kualitas pedoman. Ketersediaan pedoman saat ini di negara-
negara Asia belum dipahami dengan baik. Penilaian kritis pedoman NP di Asia 
belum dilakukan. Tujuan dari penelitian ini adalah untuk menilai kualitas 
pengobatan farmakologis dari pedoman NP di Asia. Pencarian sistematis 
dilakukan dengan menggunakan kombinasi kata kunci: nyeri neuropatik, 
Asia, dan pedoman. Evaluasi panduan menggunakan instrumen appraisal of 
guidelines for research & evaluation II (AGREE II). Hasil ini diartikan sebagai (i) 
sangat direkomendasikan untuk digunakan dalam praktik jika sebagian besar 
domain mendapat skor di atas 50%; (ii) direkomendasikan untuk digunakan 
dengan beberapa modifikasi jika sebagian besar domain mencetak antara 30% 
hingga 50%; atau (iii) tidak direkomendasikan untuk digunakan dalam praktik 
jika sebagian besar domain mendapat skor di bawah 30%. Setelah dicocokkan 
dengan kriteria inklusi dan eksklusi ada 5 pedoman yang tersisa: pedoman dari 
Filipina, Cina, Korea Selatan, Malaysia, dan Timur Tengah. Semua pedoman 
direkomendasikan untuk digunakan dengan beberapa modifikasi. Pedoman 
menyebutkan bahwa pengobatan lini pertama untuk NP adalah tricyclic 
antidepressants, selective norepinefrin reuptake inhibitor (SNRI), dan alpha 
2-delta ligand calcium channel blocker (CCB). Sebagian besar bukti berasal dari 
NP perifer. Terdapat bukti terbatas untuk pengobatan nyeri neuropatik sentral 
(nyeri post stroke sentral dan nyeri setelah cedera tulang belakang). Semua 
pedoman yang ada menyebutkan bahwa pengobatan lini pertama untuk NP 
adalah antidepresan trisiklik, SNRI, dan alpha 2-delta ligand CCB.
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INTRODUCTION
Chronic pain is the most common 
reason for visiting the outpatient clinic.1 
Neuropathic pain (NP) is a common type 
of chronic pain. NP is defined as pain 
initiated or caused by lesion or disease 
of the somatosensory system, including 
peripheral fibres (Aβ, Aδ and C fibres) and 
central neurons.2 Previous study showed 
that 7 to 8% of the population affected by 
NP. Evidences showed that as much as 
5% NP cases may be severe enough and 
intractable.3 NP reduces the quality of life 
significantly.4 It causes poor impact on 
the economy such as considerable loss in 
working days, disability and increasing 
health care costs. Therefore, NP should 
be approached as major health problem.5
Pharmacological treatment is the 
main approach in the management of 
NP.6 NP is often difficult to treat since 
due to it is resistant to many medications 
and/or due to the adverse effects 
associated with effective medications. 
Most patients require treatment with 
more than one drug. Clinicians may 
be guided by a number of published 
guidelines and algorithms for the 
management of NP.1 Clinical practice 
guidelines defined as statements that 
include recommendations intended to 
optimize patient care that are informed 
by a systematic review of the evidence 
and an assessment of the benefits and 
harms of alternative care options.6 
Clinical practice guidelines are developed 
systematically to help practitioners and 
patients choose the appropriate care for 
specific clinical situations.7
A critical appraisal is a systematic 
process used to identify the strengths and 
weaknesses of a research article in order 
to assess the usefulness and validity of 
research findings.8 As treatment is made 
based on a guideline, it is important to 
determine the quality of every guideline. 
The availability of current guideline in 
Asian countries is not well understood 
yet. Critical appraisal of NP guidelines 
in Asia has not performed, yet. The aim 
of this study was to appraise the quality 
of pharmacological treatment from NP 
guidelines in Asia.
MATERIAL AND METHODS
MATERIALS
A systematic search was performed 
by 2 authors. Guidelines were obtained 
by reviewing the major medical database 
(Pubmed and EMBASSE), homepages of 
international medical institution and 
other relevant websites. The search 
was conducted by using combination of 
keywords: neuropathic pain, Asia and 
guideline. 
The inclusion criteria i.e. (1) 
guideline from different country in 
Asia; (2) full text was available; (3) the 
guidelines were written in English; 
and (4) the guidelines were published 
between 2009 and 2017. We decided 
to only include guidelines written in 
English so that whosoever can access the 
guideline. Guidelines were excluded if 
focused on only one type of neuropathic 
pain, such as diabetic neuropathic pain. 
We excluded the guideline or consensus 
statement that did not represent the view 
of national pain organization. FIGURE 1 
below represents the selection process.
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There were 39 manuscripts found 
during systematic search. Nine of 
them were duplication, as the same 
manuscript published in the different 
database. After checking for the content 
of each manuscript, only 5 manuscripts 
meet our criteria. Irrelevant manuscripts 
were published before 2009, written in 
regional language, or did not meet the 
criteria of guideline. We expected that 
every guideline discussed in this critical 
appraisal can be beneficial by whosoever 
so that manuscript in regional language 
would be excluded.
Review Process
Selected guidelines were evaluated 
by 2 appraisers. Appraisal of guidelines 
for research and evaluation II (AGREE 
II) instrument was used as guidelines for 
evaluation. AGREE II is an instrument to 
assess the quality of guidelines.9 There 
were 23 key items organized within 6 
domains: (1) scope and purposes, (2) 
stakeholder involvement, (3) rigour of 
development, (4) clarity of presentation, 
(5) applicability, and (6) editorial 
independence. Each key item was rated 
on a 7-point scale; 1-strongly disagree to 
7-strongly agree. The key item scored 1 if 
there is no information that is relevant 
o AGREE II criteria and scored 7 if 
the key items fulfill the criteria. Score 
between 2 and 6 were assigned when the 
key items do not meet the full criteria. 
Scores in each domain calculated into a 
single quality score using the following 
formula: (obtained score – minimum 
possible score / maximum possible 
score – minimum possible score) x 
100%. The result interpreted as (i) 
a strongly recommended for use in 
practice if most domains scored above 
50%; (ii) recommended for use with 
some modification if most domains 
scored between 30% to 50%; or (iii) not 
recommended for use in practice if most 
domains scored below 30%.
The information retrieved about 
pharmacological treatment for 
each guideline. The treatment were 
summarized in a table, based on 
condition and recommendation level. 
The discussion was focused in the quality 
of each guideline.
 
39 Guidelines 
28 Guidelines 
5 Guidelines 
Duplicate Removal 
Exclude Irrelevant 
Citation 
Systematic Searches of 
Guidelines for Neuropathic Pain 
Homepages of 
International Medical 
Institution 
Websites 
 
FIGURE 1. Guidelines selection process
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TABLE 1. Neuropathic pain guidelines in Asia
Guidelines Name Organization or Insti-tute
Short 
Name
Country or 
Region
Release 
Time
Neuropathic Pain Syndromes10 Pain Society of the Phil-
ippines
PSP Philippines 2009
Handbook of Neuropathic Pain 
Management Guidelines, 2nd 
Edition11
Multidisciplinary Panel 
on Neuropathic Pain
MPNP China 2011
A Treatment Guideline for 
Neuropathic Pain12
Korean Society of Spine 
Surgery
KSSS South Korea 2011
Management of Neuropathic Pain, 
2nd Edition13
Malaysia Association 
for the Study of Pain
MASP Malaysia 2012
Guidelines for the Pharmacological 
Treatment of Peripheral Neuropathic 
Pain: Expert Panel Recommendations 
for the Middle East Region14
Square Pharmaceuticals 
Limited
SPL Middle East 2014
Those five guidelines were evaluated 
using the AGREE II instrument. All 
of guidelines are recommended for 
use with some modification. TABLE 2 
shows a summarized of the guidelines 
score for each domain. Guidelines from 
Philippines, China, Malaysia and Middle 
East show a specific recommendation 
for each condition. Korean guideline 
is the only one, which is, shows a 
general recommendation for all kind of 
neuropathic pain. The highest score was 
obtained by domain 4 and the lowest 
score was obtained by domain 5 and 
domain 6.
RESULT
A total 39 manuscripts were 
collected during the guidelines search. 
After matched to inclusion and exclusion 
criteria there are 5 guidelines left: a 
guideline from Philippines, China, South 
Korea, Malaysia and Middle East. The 
information about those guidelines 
summarized in TABLE 1.
TABLE 2. Domain scores of neuropathic pain guidelines
Organization or 
Institute
Domain 
1
Domain 
2
Domain 
3
Domain 
4
Domain 
5
Domain 
6
PSP10 55,56% 61.11% 29.17% 94.44% 29.17% 16.67%
MPNP11 83.33% 83.33% 37.5% 94.44% 29.17% 33.33%
KSSS12 55.56% 61.11% 29.17% 94.44% 25% 25%
MASP13 77.78% 66.67% 18.75% 100% 37.5% 41.67%
SPL14 61.11% 55.56% 33.33% 94.44% 33.33% 16.67%
PSP: Pain Society of the Philippines; MPNP: Multidisciplinary Panel on Neuropathic 
Pain, KSSS: Korean Society of Spine Surgery; MASP: Malaysia Association for the 
Study of Pain; SPL: Square Pharmaceuticals Limited, Domain 1: scope and purposes, 
Domain 2: stakeholder involvement, Domain 3: rigour of development, Domain 4: 
clarity of presentation, Domain 5: applicability, Domain 6: editorial independence
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TABLE 3. Summary of neuropathic drugs recommendation
Condition and
Recommendation Level
PSP10
Drugs
MPNP11 KSSS12 MASP13 SPL14
Post 
Herpetic 
Neuralgia
1st line Gabapentin, 
Pregabalin
TCA or A2D ligands 
± adjunctive local 
anaesthetic or 
EMLA cream ± 
adjunctive TENS
Pregabalin, 
Gabapentin, 
Amitriptyline, 
EMLA cream/
Capsaicin/5% 
lignocaine patch
Topical 
lidocaine (patch 
or 5% gel or 
cream)
2nd line Amitriptyline, 
Tramadol, 
Opioids, 
Oxycodone, 
Fentanyl, 
Topical 
lidocaine
Oral opioids, 
carbamazepine*
Tramadol
Diabetic 
Peripheral 
Neuropathy
1st line Pregabalin, 
Gabapentin,
Fentanyl
A2D ligands, TCAs 
or SNRIs
Pregabalin, 
Gabapentin
Amitriptyline
Duloxetine, 
Venlavaxine
2nd line Duloxetine, 
Venlavaxin, 
Oxycodone, 
Tramadol, 
Amitriptyline
Tramadol Tramadol
Central 
Post-Stroke 
Pain
1st line Lamotrigine A2D ligands or 
TCAs
Pregabalin, 
Gabapentin,
Amitriptyline, Carbamazepine
2nd line Amitriptiline, 
IV lidocaine
Other anticonvul-
sants or opioids
Opioids
3rd line Adjuctive local 
anaesthetics
Complex 
Regional 
Pain 
Syndrome
1st line 1. NSAIDs and/
or TCAs or 
anticonvulsant
2. TCA + 
anticonvulsant
3. TCA + rotation of 
anticonvulsant
Antidepressant,
Anticonvulsant,
or both
2nd line Opioids Opioids
TABLE 3 shows a summarized of the 
guidelines treatment recommendations. 
Guidelines from Philippines, China, 
Malaysia and Middle East show a specific 
recommendation for each condition. 
Korean guideline is the only one which is 
show a general recommendation for all 
kind of neuropathic pain. Most guidelines 
show that most of the evidences come 
from peripheral neuropathic condition. 
There are limited evidences in treatment 
of central neuropathic pain condition 
(central post stroke pain or spinal cord 
injury). The evidences about using 
combination therapy in neuropathic 
pain are very limited. Most of the 
recommendation for central neuropathic 
pain comes from small clinical trial 
and expert opinions. The combination 
therapy recommendation comes from 
expert opinion. There are also limited 
evidences in radicular pain condition, 
which is a condition that very common 
in our daily clinical practice.
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3rd line Corticosteroids Lignocaine,
Ketamine
4th line 1. Lignocaine, 
capsaicin, or 
transdermal 
fentanyl
2. Calcitonin, 
bisphosphonates
Neuralgia 
Trigeminal
1st line Carbamazepine* Carbamazepine, 
Oxcarbazepine
2nd line A2D ligands, other 
anticonvulsants, 
antidepressants
Baclofen, 
Lamotrigine
Gabapentin, 
Pregabalin, 
Amitriptyline, 
Duloxetine
Cancer 
Pain
1st line A2D ligand 
(pregabalin, 
gabapentin) and/
or TCA
2nd line Other 
anticonvulsant and 
antidepressant
3rd line Other agents 
(systemic ketamine 
or lignocaine)
Spinal Cord 
Pathologies
1st line A2D ligands, TCAs
2nd line Other 
anticonvulsant, 
opioids
3rd line Intravenous 
ketamine, invasive 
procedures
Persistent 
Post-
Surgical 
Pain
1st line Pregabalin, 
Gabapentin, 
Amitriptyline, 
Duloxetine
2nd line Tramadol
1st line TCAs
Gabapentin, 
Pregabalin, 
local 
Lidocaine 
products
A2D ligand 
(pregabalin, 
gabapentin), 
TCAs 
(nortriptyline, 
desipramine)
2nd line Opioid, 
Tramadol
SNRI 
(venlafaxine 
XR, duloxetine), 
opioid 
(tramadol, 
oxycodone)
3rd line Duloxetin, 
Venlavaxine
PSP: Pain Society of the Philippines; MPNP: Multidisciplinary Panel on Neuropathic Pain, KSSS: Korean Society of 
Spine Surgery; MASP: Malaysia Association for the Study of Pain; SPL: Square Pharmaceuticals Limited; TCA: Tricyclic 
Antidepressant; A2D: Alpha-2-delta, EMLA: Eutectic Mixture of Local Anaesthetics; TENS: Transcutaneous Electrical 
Nerve Stimulation; SNRI: Selective Norepinephiren Reuptake Inhibitor
*Genetic susceptibility for Stevens-Johnson Syndrome (HLA-B1502) should be assessed in Asia patients before 
commencing treatment with carbamazepine
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DISCUSSION
Our result of assessments showed 
that all guidelines are recommended 
for use with some modification. The 
recommendations from all guidelines are 
specific, unambiguous, clearly presented 
and easily identifiable.
The AGREE II instrument was used 
as guidelines for evaluation with 23 
key items organized within 6 domains. 
Domain 1 is “scope and purposes”, is 
concerned with the overall aim of the 
guideline, the specific health questions, 
and the target population (items 1-3). 
Domain 2 is “stakeholder involvement”, 
focuses on the extent to which the 
guideline was developed by the 
appropriate stakeholders and represents 
the views of its intended users (items 
4-6). Domain 3 is “rigor of development”, 
relates to the process used to gather and 
synthesize the evidence, the methods 
to formulate the recommendations and 
to update them (items 7-14). Domain 
4 is “clarity of presentation”, deals 
with the language, structure and the 
format of the guideline (items 15-17). 
Domain 5 is “applicability”, pertains 
to the likely barriers and facilitators to 
implementation, strategies to improve 
uptake and resource implications of 
applying the guideline (items 18-21). 
Domain 6 is “editorial independence”, 
is concerned with the formulation of 
recommendations not being unduly 
biased with competing interests (items 
22-23).9
The highest score was obtained 
by the domain 4, which means the 
guidelines had a good description 
of the recommendations. The 
recommendations from all guidelines 
are specific, unambiguous, clearly 
presented and easily identifiable. The 
recommendations were summarized 
in TABLE 3. All guidelines describe the 
qualifying condition and side effects 
of each recommendation clearly. The 
recommendations grouped together 
in one section and presented as flow 
charts or a summarized box. A2D ligands 
(gabapentin and pregabalin) and/or TCAs 
(amitriptyline) are the first line therapy 
for almost all type of neuropathic 
pain. Post herpetic neuralgia, diabetic 
peripheral neuropathy and central post 
stroke pain were the most common 
conditions discussed. 
Domain 1 and 2 also had good 
scores. All guidelines were described 
the objective(s) specifically. The target 
population and clinical condition were 
mentioned clearly, that is neuropathic 
pain patients. The target user of 
guidelines was physicians, but the 
guideline from Philippine and Korea 
did not mention it clearly. Most of 
the guidelines’s development group 
was included individual from various 
professional group, such as physicians, 
neurologist and anesthesiologist. Middle 
East’s guideline is the only one which 
didn’t describe the development group 
clearly. All guidelines in this study were 
used a literature review methods.
Domain 3 is important because it is 
evaluates the integrity of the guideline 
development process, but all those five 
guidelines did not show a high score at 
the domain 3. Guideline reviewed by 
external reviewer prior to its publication 
is necessity and Philippine guideline 
was the only one guideline mentioned 
its external reviewer. All guidelines did 
not describe their details of strategy 
used to search for evidence, criteria for 
selecting the evidence, recommendation 
development process and procedure for 
updating the guideline clearly. 
 The lowest score was obtained 
by the domain 5 and domain 6 which 
is mean the guidelines have many 
shortcomings because lack of the 
related information. Those guidelines 
had a poor description of barriers and 
facilitators to implementation, potential 
resource implications of applying 
recommendations, monitoring and/
or auditing criteria, a statement of not 
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biased with competing interests. 
The treatment recommendations 
were summarized in TABLE 2. All 
guidelines describe the qualifying 
condition and side effects of each 
recommendation clearly. The 
recommendations grouped together 
in one section and presented as flow 
charts or a summarized box. A2D ligands 
(gabapentin and pregabalin) and/or 
TCAs (amitriptyline) are the first line 
therapy for almost all type of NP. Post 
herpetic neuralgia, diabetic peripheral 
neuropathy and central post stroke 
pain were the most common conditions 
discussed. There are limited evidences 
in treatment of central NP condition 
(central post stroke pain or spinal cord 
injury).
CONCLUSION
Five Asian guidelines fulfill the 
satisfying criteria according to AGREE 
II instrument, eventhough need some 
modification. The available guidelines 
describe the medicine recommendations 
specific, unambiguous, clearly presented 
and easily identifiable. Tricyclic 
antidepressant, SNRI, and A2D ligand 
CCB are the first line treatment for 
various neuropathic pain condition.
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